Driven by massively parallel sequencing and allied technologies, the scale of genetic predisposition testing is on a dramatic uptrend. While many patients are found to carry clinically actionable pathogenic sequence variants, testing also reveals enormous numbers of Unclassified 
Introduction
Inactivating mutations in BRCA1 (MIM #113705) are associated with an increased risk of breast and ovarian cancer. While many patients who undergo clinical mutation testing are found to carry clinically actionable pathogenic sequence variants, testing also reveals large numbers of Unclassified Variants (UV), or Variants of Uncertain Significance (VUS), most of which are rare missense substitutions. All known pathogenic non-spliceogenic BRCA1 missense substitutions are found in the N-terminal RING domain and C-terminal BRCT domains (Easton et al. 2007; Lindor et al. 2012; Vallée et al. 2012) . The RING domain binds BARD1, enabling rapid recruitment to sites of DNA damage and generating an E3 ubiquitin ligase (Li and Yu 2013; Densham et al. 2016) , and the BRCT domains bind a number of proteins involved in the DNA damage response (reviewed in Mermershtain and Glover 2013). Many functional assays have been developed to test the impact of missense substitutions on these functionally important domains, and other regions of the BRCA1 protein.
The BRCA gene Ex-UV database (hci-exlovd.hci.utah.edu) contains BRCA1 and BRCA2 UVs clinically classified or reclassified using a quantitative Integrated Evaluation (QIE, also known as multifactorial likelihood analysis) (Vallée et al. 2012) . The classifications are based on calibrated sequence analysis to generate a prior probability of pathogenicity (Prior P), patient observational data to generate odds in favor of pathogenicity, and Bayes rule to combine these data into a posterior probability of pathogenicity (Posterior P). For purposes of clinical translation and patient counselling/management, the Posterior P is translated through the IARC 5-category classifier (Plon et al. 2008) . Currently the database includes fields for sequence analysis-based Prior Ps for missense analysis (Tavtigian et al. 2008) , and predicted effects on splicing (Vallée et al. 2016) . It also includes odds in favor of pathogenicity in the form of ! ! likelihood ratios (LR) for co-segregation with cancer phenotype (Thompson et al. 2003) , strength of personal and family cancer history (Easton et al. 2007) , tumor pathology (Chenevix-Trench et al. 2006; Spurdle et al. 2008 Spurdle et al. , 2014 , and co-occurrence with known pathogenic variants (Goldgar et al. 2004) ; the product of these four LRs is the observational LR in favor of pathogenicity (Obs LR).
The rate-limiting step in UV classification has been accumulation of sufficient Obs LR from patient observational data to modify the Prior P into a Posterior P >0.95 (likely pathogenic) or <0.05 (likely not pathogenic/likely neutral). Functional assay estimates of damage to protein function can be used as a proxy for pathogenicity if the assay outputs are empirically calibrated (either against known pathogenic and known neutral variants or against patient observational data) to read out a variable that is more directly related to pathogenicity e.g., a functional likelihood ratio in favor of pathogenicity (Functional LR). Once such a calibration is in place and the functional assay(s) are considered sufficiently accurate for use in clinical variant classification, the assay(s) can become directly useful for medical genetics related evaluation of missense substitutions and other UVs. In principle, the QIE enables classification through a twocomponent combination of sequence-based in silico analyses and a calibrated functional assay.
In the companion article (Paquette et al., submitted and bioRxiv 092619; doi: http://dx.doi.org/10.1101/092619) we describe the calibration of a mammalian two-hybrid assay testing BARD1 binding capabilities of BRCA1 RING domain substitutions. In addition, Woods et al. (2016) recently described the calibration of mammalian transcriptional activation (TA) assays for evaluation of missense substitutions in the BRCA1 C-terminal region. Here we report an update of the BRCA1 Ex-UV database to incorporate a Functional LR based on these ! ! calibrated functional assays into the Integrated Evaluation of BRCA1 sequence variants. This has led to the addition of 152 variants to the database.!
Methods

MIM # and accession #
BRCA1 is MIM# 113705, and exonic variant coding used here is based on NM_007294.3.
Database updates
Three new fields have been added to the LOVD BRCA1 Ex-UV database (hciexlovd.hci.utah.edu, under the gene database BRCA1fx): Functional LR, Functional Assay Reference, and Clinical Severity. The Clinical Severity field will be used to differentiate pathogenic variants (i.e. confers medically actionable increased risk) associated with different levels of risk. The values used to populate Clinical Severity are high-risk, moderate-risk, and not applicable. The Clinical Severity category is assigned to a variant based on the estimated cumulative risks to age 80: high-risk >32%; moderate-risk 18-32% (Easton et al. 2015) . Variants assigned to Class 5 or Class 4 by QIE are assumed to be high-risk unless patient observational data in the form of co-segregation with the cancer phenotype, strength of personal and family cancer history, or a case-control odds ratio are indicative of moderate-risk. At this time, p.R1699Q is the only proven moderate-risk BRCA1 variant (Spurdle et al. 2012) . Clinical Severity for variants assigned to Class 3, Class 2, or Class 1 by QIE are marked not applicable.
The other functional assay-related LOVD fields are populated based on the functional assay data available in the 'datasets' section described below.
Datasets
! !
Only missense substitutions that have been observed in cases were added to the LOVD database, due to assumed contribution of a minimal observational datum (personal history of cancer) in the derivation of the sequence analysis Prior P and Functional LR. For the BRCA1 RING domain (aa 2−103), there were 10 natural (i.e. originally identified in cancer cases) already classified missense substitutions recorded in the Ex-UV database, and an additional UV (p.P34S). Because only two variants were neutral, the assay calibration described in the companion research article (Paquette et al., submitted and bioRxiv 092619; doi: http://dx.doi.org/10.1101/092619) included three human Class 3 substitutions with Obs LR <0.50, plus four cross-species multiple sequence alignment neutral missense substitutions (viz, the alternate amino acid is present in a non-human primate and within the range of variation at it's position in a mammals-only BRCA1 protein multiple sequence alignment even if the specific primate with that residue is excluded from the alignment). To avoid circularities, the variants used in assay calibration in Paquette et al. (submitted and bioRxiv 092619; doi: http://dx.doi.org/10.1101/092619) are not included here. There are 242 'natural' BRCA1 missense substitutions between amino acids 1,315-1,863 evaluated in Woods et al. (2016) , including 36 variants that were used as internal standards in calibration of the transactivation assay. These were in Lindor et al. (2012) as IARC Class 1, Not Pathogenic (n=19); Class 4, Likely Pathogenic (n=1); and Class 5, Pathogenic (n=14). One of the 'neutral' variants (c.4484G>T p.R1495M) is actually a spliceogenic pathogenic variant (Colombo et al. 2013) , and the moderate-risk variant p.R1699Q was assigned to Class 5. A further two Class 1 variants were classified by the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Consortium (data not shown). As with the RING domain variants these were not added to the BRCA1fx database to avoid circularities. The remaining 206 variants include 12 in ! ! the coiled-coil domain (aa 1,392-1,424); 117 over the BRCT1, linker, and BRCT2 domains (aa 1,650-1,859); and 73 in the interval between the coiled-coil and BRCT1. The missense analysis Prior P and splicing Prior P for each variant are taken from the HCI Breast Cancer Genes Prior Probabilities database (priors.hci.utah.edu/PRIORS) (Vallée et al. 2016 ).
Derivation of Functional LR
The derivation of the functional Odds Path for the BRCA1 RING domain missense substitutions is described in the companion article (Paquette et al submitted and bioRxiv 092619; doi: http://dx.doi.org/10.1101/092619). For the missense substitutions in Woods et al. (2016) the supplementary materials provided the data used to derive the Functional LR. They used a Bayesian hierarchical model (called VarCall) that takes into account experimental heterogeneity in the in cellulo functional assay to estimate log e odds in favor of pathogenicity (L e LR) for each variant tested (Iversen et al. 2011; Woods et al. 2016) .
Unlike the mammalian two-hybrid assay described in the companion article (Paquette et al submitted and bioRxiv 092619; doi: http://dx.doi.org/10.1101/092619), the TA assay does not directly test the underlying mechanism causing pathogenicity of a missense substitution in the Cterminus. For example, it is unable to discriminate the moderate-risk pathogenic variant BRCA1 p.R1699Q from high-risk pathogenic variant p.R1699W. Thus, we wanted to introduce a degree of uncertainty to the calculation of the Functional LR, through constraining the L e LR to act as a safe-guard against misclassification based on evaluation by two-component QIE. Previously classified variants on the Ex-UV database (n=38, Supp. Table S1 ) were used to define the zone of uncertainty, which informed the value used to constrain the log e odds estimated by VarCall. The constrained Functional LR was then calculated by exponentiation of the constrained L e LR.
Statistical analyses
! !
Sensitivity was calculated as (# true pathogenic variants detected by a classifier / total # true pathogenic variants). Specificity was calculated as (# true neutral variants detected by a classifier / total # true neutral variants). Error rate was calculated as [(# false pathogenic variants + # false neutral variants detected by a classifier) / (total # true pathogenic variants + # true neutral variants)]. 95% confidence intervals on these proportions were estimated using the binomial confidence interval calculator in STATA 13.1 (StataCorp).
We explored how sensitive two-component QIE would be to misspecification of either the missense analysis Prior Ps or the constrained Functional LRs. For this analysis, we assumed that the total number of misclassified variants could be estimated from their Posterior Ps, if these were accurate. For groups of pathogenic variants, the estimated number or errors would be given by equation 1, and for groups of neutral variants by equation 2:
Eq1 Eq2
Where n is an index number for each variant in the group and PP is the corresponding Posterior P. The misclassification rate would simply be the estimated number of misclassified variants divided by n, with the understanding that a rate >0.05 would violate the IARC guideline for the likely neutral or likely pathogenic categories.
Results and Discussion
Embedding quantitative integrated evaluation, with inclusion of calibrated functional assays, in a decision tree. that these data are discordant because they are on opposite sides of neutrality, but both results indicate uncertainty. So, it would be perfectly reasonable to combine these into a Posterior P, which would be 0.50. A more interesting situation would be if the missense analysis Prior P gave 2-fold evidence against pathogenicity (naively, Prior P = 0.33) and functional assay gave 2-fold evidence in favor (Functional LR = 2.0). Here, we think that it's fair to say that they "disagree". So, we propose that if the missense analysis Prior P and Functional LR are on opposite sides of a factor-of-2 window around neutrality, we will NOT combine them via a twocomponent QIE, and the missense substitution remains Unclassified. For BRCA1, a small complication is that the background Prior P for an individual rare missense substitution is Fig. 1 , node 4). Since the functional assays evaluated here do not assess spliceogenicity, the overall probability of pathogenicity remains >0.05 and is given by the splicing Prior P. In this case, the missense substitution remains Unclassified. Note that this issue is explicitly asymmetric. If the Bayesian combination of the missense analysis Prior P and Functional LR results in a probability of pathogenicity >0.95, but the splicing Prior P <0.05, the substitution has Post P >0.95 and can be considered IARC Class 4, Likely Pathogenic. For missense substitutions that pass node 4, the Post P is used to place the substitution on a truncated 3 Class version of the IARC classifier.
Class 4 -Likely pathogenic: Posterior P >0.95
Class 3 -Uncertain: Posterior P ≥0.05 & ≤0.95
Class 2 -Likely not pathogenic: Posterior P <0.05
Moving back to node 2, if the observational/expected Obs LR criterion is met, multicomponent QIE can be applied and the analysis moves to node 5. Here, the question is ! ! much the same as at node 4: which is higher, the Bayesian combination of the missense analysis Prior P and Functional LR, or the splicing Prior P? If the splicing Prior P is greater, suggesting that there is a high probability the variant is spliceogenic, the Obs LR from patient data only is applied to this probability to calculate the missense substitution's Post P. Otherwise, the missense analysis Prior P is applied to the Obs LR derived from patient data and Functional LR.
The Post P is then used to place the substitution in the standard 5 Class IARC classifier (Plon et al. 2008 ).
Safeguards against UV misclassification built into the decision tree and quantitative
integrated evaluation with functional assay likelihood ratios.
As integrated within the decision tree of Figure 1 , QIE with Functional LRs includes five specific safeguards designed to reduce the risk of UV misclassification. These safeguards will also result in some UVs that would have been correctly classified instead resting as Unclassified pending accumulation of further data. 2. Data from the classified variants used to train VarCall (n=28, Supp. Table S1 ) Iversen et al.
(2011) or Woods et al. (2016) presented a notable lack of variants with L e LR between -2 and + 2 ( Fig. 2A ). This means that the % wildtype activity corresponding to the tipping point where the TA assay result switches from evidence against pathogenicity to evidence for pathogenicity was interpolated from variants with activities well above and below that point, http://dx.doi.org/10.1101/092619), we were not able to derive confidence intervals for the TA assay calibration. Figure 2B , corresponding to Table 1 , shows the conversion from the reported L e LR to constrained L e LR for the missense substitutions tested in the C-terminus.
After exponentiation of the constrained L e LR to derive the constrained Functional LR, the variants can enter the decision tree. and their splicing Prior P is > the Bayesian combination of the missense analysis Prior P and the Functional LR. Potentially spliceogenic missense substitutions that could damage a splice donor, damage a splice acceptor, or create a de novo donor are caught by this safeguard, specifically reducing the probability of false negative classification through QIE.
Performance on previously classified variants with patient observational data.
To get some idea of the performance of classification based on sequence analysis Prior Ps and constrained Functional LRs alone, we subjected 38 variants previously classified as likely pathogenic (Class 4, n=1; Class 5, n=15) and likely neutral (Class 2, n=2; Class 1, n=20) to the two-component evaluation (Supp. (Fig. 4) . The constrained Functional LR would have to have been inflated by more than a factor of 5 for the error rate to reach 0.025, and buy more than a factor of 15 for the error rate to reach 0.05 (Fig. 4A) . As a third alternative, the missense analysis Prior P and constrained Functional LR could be partially non-independent, so combining their full magnitude via Bayes' rule might over-estimate the Posterior P. Since the missense analysis Prior Ps were calibrated several years before the functional assays, this was tested by reducing the magnitude of the Functional LR used to calculate the Posterior P. The linear deflation described above was one test. As the Functional LRs were reported in Woods et al. (2016) as L e LR, we also tested linear deflation of the constrained L e LR (Fig. 4B) . The constrained Functional LRs would have to have been inflated to the 1.9 th power to produce an error rate of ~0.025 and to the 2.7 th power for the error rate to exceed 0.05.
The 102 likely neutral substitutions break into two sub-groups: 72 falling outside of the BRCT1-linker-BRCT2 key domain, and 30 falling within the key domain (see Fig. 3 ). The 70 upstream substitutions fall in an interval where there is no evidence for pathogenic missense substitutions except for those that damage mRNA splicing, so we did not perform any analysis.
The 30 in-domain substitutions have an estimated error rate of 0.0044. These are all Align-GVGD C0 substitutions with missense analysis Prior Ps of 0.03. Testing the possibility that this missense analysis Prior P is under-estimated, increasing it to the published 95% upper bound of the confidence interval (0.06) increased the expected error rate to 0.009. If the actual Prior P was 0.15, then the estimated error rate would be ~0.025 (Fig. 4C) , and if the prior was 0.30 the error rate would be ~0.05. Alternatively, the Functional LRs could be deflated. Testing the ! ! consequence of this possibility, we estimated the error rate as a function of constrained Functional LR reflation (Fig. 4A) . The constrained Functional LR would have to have been deflated by more than a factor of 5 for the error rate to reach 0.025, and buy more than a factor of 10 for the error rate to reach 0.05. Since the missense analysis Prior P point estimate for these substitutions is below 0.05, and almost all of the relevant constrained Functional LRs are <1.0, linear inflation of the L e LR, simulating non-independence between the missense anlaysis Prior P and the constrained Functional LR does not model a false classification rate.
Towards en masse classification
None of the 84 BRCA1 missense substitutions between the coiled-coil and BRCT domains (aa 1,425-1,649) demonstrated loss of function in the TA assay (see Fig. 3 ). Using personal and summary family history data, it has previously been shown that non-spliceogenic missense substitutions falling outside of the key functional domains are associated with <2% probability of pathogenicity (Easton et al. 2007; Tavtigian et al. 2008; Vallée et al. 2016) . Those results, which were based on patient observational data, are further supported by the functional assay data. Thus, one could begin to argue that all 1,410 non-spliceogenic (splicing Prior P <0.05) missense substitutions reachable by a single nucleotide substitution within this 225 amino acid segment could be a priori classified as Class 2, Likely Not Pathogenic.
Recently, an alternative probabilistic functional assay classification framework has been published called the ProClass toolbox (Thouvenot et al. 2016) . We attempted to compare the two models using the raw TA assay data reported in the supplementary material of Woods et al.
(2016). However, we found that ProClass in its current form could not utilize the full experimental dataset, because it could not cope with large variation between experiments for ! ! variants that had been assayed in multiple batches. Thus, we opted to use the L e LR generated by
VarCall.
In If we look back on our results 10 years from now and find that >2.5% of Likely Pathogenic variants were actually neutral, it will mean that these methods were mis-calibrated and insufficiently stringent. But if we look back 10 years from now and find that <1.0% of Likely Pathogenic variants were actually neutral, it will mean that the classification was too stringent -in fact equivalent to the Definitely Pathogenic criterion. It will also mean that fewer UVs were classified than could have been, and that fewer patients and their at-risk relatives benefited from genotype-based genetic counseling than could have been the case. The classification error rate observed when two-component QIE was applied to known neutral and known pathogenic BRCA1 missense substitutions was 0.00. In addition, the two-component classification model appears to be reasonably robust to systematic errors in the form of (1) NA -not applicable. Node 3 and 4 refer to the nodes in the decision tree of Figure 1 , which explains why the sequence variant remains 'unclassified'.
